279 related articles for article (PubMed ID: 18275906)
1. Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].
Kozikowski AP; Reitz AB
Drug Discov Today; 2008 Feb; 13(3-4):97-8. PubMed ID: 18275906
[No Abstract] [Full Text] [Related]
2. Drug discovery veers off target.
Shaffer C
Drug Discov Today; 2005 Nov; 10(22):1489. PubMed ID: 16257367
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery chemistry: a primer for the non-specialist.
Jordan AM; Roughley SD
Drug Discov Today; 2009 Aug; 14(15-16):731-44. PubMed ID: 19416759
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery alliances.
Jones A; Clifford L
Nat Rev Drug Discov; 2005 Oct; 4(10):807-8. PubMed ID: 16237845
[No Abstract] [Full Text] [Related]
5. Chinese drug research. Novartis invests $100 million in Shanghai.
Stone R; Xin H
Science; 2006 Nov; 314(5802):1064-5. PubMed ID: 17110546
[No Abstract] [Full Text] [Related]
6. Compound scale-up at the discovery-development interface.
Nikitenko AA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
[TBL] [Abstract][Full Text] [Related]
7. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
8. Dealing with drug dependency: a commentary on ILAE's partnership with the pharmaceutical industry.
Avanzini G; Engel J
Epilepsia; 2007 Oct; 48(10):1821-4. PubMed ID: 17683507
[No Abstract] [Full Text] [Related]
9. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
10. Drug discovery and development for neglected parasitic diseases.
Renslo AR; McKerrow JH
Nat Chem Biol; 2006 Dec; 2(12):701-10. PubMed ID: 17108988
[TBL] [Abstract][Full Text] [Related]
11. Opening opportunities for new drugs against neglected diseases.
Costi MP; Taramelli D; González-Pacanowska D
ChemMedChem; 2008 Mar; 3(3):371-3. PubMed ID: 18324713
[No Abstract] [Full Text] [Related]
12. A maturing European Research Council.
Nat Cell Biol; 2010 Apr; 12(4):307. PubMed ID: 20360745
[No Abstract] [Full Text] [Related]
13. Scripps Florida.
Sheppard TL
Nat Chem Biol; 2007 Aug; 3(8):451. PubMed ID: 17637772
[TBL] [Abstract][Full Text] [Related]
14. Mark Fishman on changing the grammar of drug discovery. Interviewed by Christopher Watson.
Fishman M
Drug Discov Today; 2005 May; 10(9):609-11. PubMed ID: 15894223
[No Abstract] [Full Text] [Related]
15. Transatlantic regulatory cooperation expanded.
Hughes B
Nat Rev Drug Discov; 2007 Aug; 6(8):589-90. PubMed ID: 17821826
[No Abstract] [Full Text] [Related]
16. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
Shumoogam J; Al-Shamahi A
IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
[TBL] [Abstract][Full Text] [Related]
17. Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.
Adam M
Stud Hist Philos Biol Biomed Sci; 2005 Sep; 36(3):513-37. PubMed ID: 16137601
[TBL] [Abstract][Full Text] [Related]
18. Developing drugs for parasitic diseases.
Andreopoulos S
Science; 2003 Apr; 300(5618):430-1. PubMed ID: 12702858
[No Abstract] [Full Text] [Related]
19. Grassroots initiatives.
Maxmen A
Nature; 2010 Jul; 466(7304):S20. PubMed ID: 20631701
[No Abstract] [Full Text] [Related]
20. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
Rai AK; Reichman JH; Uhlir PF; Crossman C
Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
